Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 363-365 , September 2007

Introduction: Chronic lymphocytic leukemia in perspective

  • Kanti R. Rai, MD (Chief, Division of Hematology-Oncology, Long Island Jewish Medical Center, New Hyde Park, NY, and Joel Finkelstein Cancer Foundation Professor of Medicine, Albert Einstein College of Medicine, Bronx, NY)

      Affiliations

    • Corresponding Author InformationTel.: +1 718 470 7135; Fax: +1 718 347 6073.

References 

  1. Chiorazzi N, Rai KR, Ferrarini M. Mechanisim of disease: Chronic lymphocytic leukemia. The New England Journal of Medicine. 2005;352:804–815
  2. Binet J-L, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006;107:859–861
  3. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine. 2000;343:1910–1916
  4. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as s surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The New England Journal of Medicine. 2003;348:1764–1775
  5. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine. 2004;351:893–901
  6. Krober A, Bloehdom J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in CLL. The Journal of Clinical Oncology. 2006;24:969–975
  7. Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in CLL. Blood. 1999;94:1840–1847
  8. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in CLL, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–1029
  9. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of CLL derived from a multivariate survival analysis. Cancer. 1981;48:198–206
  10. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical Staging of CLL. Blood. 1975;46:219–234
  11. Rai K. A critical analysis of staging in CLL. In:  Gale RP,  Rai KR editor. CLL: Recent Progress, Future Direction. New York: Alan R Liss; 1987;p. 253
  12. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular Kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755–764
  13. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute – sponsored Working Group guidelines for CLL: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997

PII: S1521-6926(07)00045-X

doi: 10.1016/j.beha.2007.03.008

Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 363-365 , September 2007

Article Tools